Brind.

Analysis Compares Perrigo and Ovid Therapeutics in Healthcare Sector

1 report, 1 independent Updated Oct 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Perrigo Company Plc and Ovid Therapeutics was published on October 20, 2026, contrasting the two healthcare companies across several financial metrics. The report noted that Ovid Therapeutics has lower revenue but higher earnings than Perrigo Company Plc. Furthermore, Ovid Therapeutics trades at a lower price-to-earnings ratio than Perrigo Company Plc, and its stock has a beta of 0.22 compared to Perrigo Company Plc's beta of 0.69.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison details differences in profitability, risk, and ownership structure between the two firms. Perrigo Company Plc has 95.9% of its shares owned by institutional investors, while Ovid Therapeutics has 72.2% institutional ownership. These metrics provide insight into investor sentiment and relative market valuations.

From themarketsdaily.com

Who's involved

  • Perrigo Company PlcPharmaceutical company whose stock is being compared against Ovid Therapeutics
  • MarketBeatTechnology platform that aggregates and provides analyst ratings for Perrigo Company Plc

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Perrigo Company PlcSpeculative

    Perrigo Company Plc might face increased competitive pressure on its market price due to the comparative analysis suggesting Ovid Therapeutics is more favorable.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped